MO-1, A Gene Associated With Morbid Obesity
AssigneeMt. Sinai School of Medicine
InventorsAdel Shalata, JOHN Martignetti, Robert Desnick
Life of this patent
Estimating the term…
Abstract
MO-1 is a newly identified gene and gene product associated with morbid obesity. Isolated MO-1 nucleic acids, MO-1 polypeptides, oligonucleotides that hybridize to MO-1 nucleic adds, and vectors, including expression vectors, comprising MO-1 nucleic acids are disclosed, as are isolated host cells, antibodies, transgenic non-human animals, compositions, and kits relating to MO-1. Methods of detecting the presence of MO-1 nucleic acid, screening for agents which affect MO-1 activity, and screening for MO-1 variants are also disclosed.
Claims79
An isolated nucleic acid encoding a polypeptide comprising an amino acid sequence having at least 70% identity to SEQ ID NO:1.
An isolated polypeptide comprising an amino acid sequence having at least 70% identity to SEQ ID NO:1.
An isolated polypeptide comprising an amino acid sequence having at least 70% identity to amino acids 1-81 of SEQ ID NO:1.
An isolated oligonucleotide comprising at least 10 consecutive nucleotides of SEQ ID NO:2 or its complementary strand.
An isolated oligonucleotide comprising at least 10 consecutive nucleotides of SEQ ID NO:3 or its complementary strand.
An isolated antibody that specifically binds to a polypeptide comprising an amino acid sequence of SEQ ID NO:1.
A transgenic non-human animal, which expresses a nucleic acid encoding a MO-1 polypeptide.
A transgenic non-human animal whose germ cells comprise a homozygous null mutation in the endogenous nucleic acid sequence encoding MO-1, wherein the mutation is created by insertion of a neomycin cassette, in reverse orientation to MO-1 transcription and wherein said mutation has been introduced into said animal by homologous recombination in an embryonic stem cell such that said animal does not express a functional MO-1 polypeptide.
A method of screening for an agent which affects MO-1 activity, comprising:
- a) contacting said agent to a cell that expresses a MO-1 polypeptide;
- and b) assessing a biological activity of the MO-1 in the cell.
A composition comprising a polypeptide having an amino acid sequence that comprises SEQ ID NO:1 and a pharmaceutically acceptable carrier.
A composition comprising a polynucleotide encoding a polypeptide having an amino acid sequence that comprises SEQ ID NO:1 and a pharmaceutically acceptable carrier.
A kit comprising i) an isolated oligonucleotide comprising at least 10 consecutive nucleotides of SEQ ID NO:2 or its complementary strand and ii) a container.
A kit comprising i) an isolated oligonucleotide comprising at least 10 consecutive nucleotides of SEQ ID NO:3 or its complementary strand and ii) a container.
A method of producing a MO-1 polypeptide in a host cell comprising:
- i) transforming the host cell with a nucleic acid sequence encoding the MO-1 polypeptide;
- and ii) expressing the nucleic acid sequence so that the MO-1 polypeptide is produced by the host cell.
A method of treating a condition associated with MO-1, comprising administering a MO-1 polypeptide to a subject in need thereof, thereby treating the condition.
A method of increasing the weight of a subject, comprising administering a MO-1 polypeptide to a subject in need thereof, thereby increasing the weight of the subject.
A method of treating a condition associated with MO-1, comprising administering a nucleic acid that increases expression of a MO-1 polypeptide to a subject in need thereof, thereby treating the condition.
Dependencies are inferred from the claim text.